Key result
The future of drug-eluting stents lies in the development of better stents with new designs, improved biological polymers, and novel drugs to prevent in-stent restenosis.
Future advancements in percutaneous coronary intervention will rely on innovative drug-eluting stent technologies to overcome current limitations like in-stent restenosis and late thrombosis.
Should not yet change stent selection in PCI; leaves open which new designs or polymers will best reduce restenosis.
In-stent restenosis (ISR) is the major drawback of percutaneous coronary interventions, occurring in 10-40% of patients. Drug eluting stents (DES) are successful in a large majority of patients in preventing restenosis for the first year after implantation. Recently, new stents have emerged that are loaded with anti-inflammatory, antimigratory, antiproliferative, or pro-healing drugs. These drugs are supposed to inhibit inflammation and neointimal growth and subsequently ISR. The future of DES lies in the development of better stents with new stent designs, better polymers including biological polymers and biological biodissolvable stent coatings, and new, better drugs.
No takes yet. Share an insight, caveat, or question.
Anis et al. (2005) conducted a review in In-stent restenosis. Drug eluting stents (DES) was evaluated. The future of drug-eluting stents lies in the development of better stents with new designs, improved biological polymers, and novel drugs to prevent in-stent restenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: